In this context, treatment with obeticolic acid, a farnesoid X receptor (FXR) agonist, showed a significant reduction in ALP levels in patients with PSC, suggesting that modulation of biliary metabolism may be a promising therapeutic target in PSC-IBD [42]. The gene discussed is NR1H4; the disease is inflammatory bowel disease.